(ANSA) – BEIJING, 09 DEC – The Chinese drug authority has granted emergency approval for the country’s first specialized treatment against Covid-19, which in clinical studies significantly reduces hospitalizations and deaths among high-risk patients risk.
The move has matured as authorities around the world are giving the green light to treatments, particularly in favor of high-risk groups, due to fears about the new Omicron variant of Covid. China is also grappling with a growing number of studies showing that its vaccines are characterized by a lower efficacy rate than those produced abroad.
In an official notice released Wednesday, the National Medical Products Administration said it had granted “emergency approval” for a treatment with monoclonal antibodies, which are a type of protein that binds to the coronavirus, reducing its ability to enter cells. of the body.
The treatment, co-developed by Tsinghua University, Third People’s Hospital in Shenzhen and Brii Biosciences, involves a combination of two drugs, administered via injections, which can be used to curb the progression of the disease, the pharmaceutical authority explained. (HANDLE).
REPRODUCTION RESERVED © Copyright ANSA
Get the embed code